Osteocalcin: A pivotal mediator or an innocent bystander in energy metabolism?

Nephrology Dialysis Transplantation

Volumn 26, Issue 1, 2011, Pages 42-45

  Razzaque, Mohammed Shawkat ^a  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

glucose metabolism; insulin; osteoblast; osteocalcin

Indexed keywords

ADIPONECTIN; ALKALINE PHOSPHATASE BONE ISOENZYME; ESTROGEN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN RECEPTOR; OSTEOCALCIN; PROTEIN TYROSINE PHOSPHATASE; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA VALVE DISEASE; ARTICLE; BONE; BONE DENSITY; BONE DISEASE; BONE MINERAL; CALCIFICATION; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; ENERGY METABOLISM; FRACTURE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMODIALYSIS PATIENT; HIP FRACTURE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY; KIDNEY FUNCTION; MOUSE; NONHUMAN; OBESITY; OSTEOBLAST; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE;

CHRONIC DISEASE; ENERGY METABOLISM; GLUCOSE; HUMANS; INSULIN RESISTANCE; KIDNEY DISEASES; OSTEOCALCIN;

EID: 78650641156     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq721     Document Type: Article

References (42)

1. Hruska KA, Saab G, Mathew S et al. Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial 2007; 20: 309-315
2. Alem AM, Sherrard DJ, Gillen DL et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58: 396-399
3. Kobayashi S, Maesato K, Moriya H et al. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 2005; 45: 275-280
4. Chen J, Muntner P, Hamm LL et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 2003; 14: 469-477
5. Fulzele K, Riddle RC, Digirolamo DJ et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 2010; 142: 309-319
6. Ferron M, Wei J, Yoshizawa T et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010; 142: 296-308
7. Grigoriadis AE, Heersche JN, Aubin JE. Differentiation of muscle, fat, cartilage, and bone from progenitor cells present in a bone-derived clonal cell population: effect of dexamethasone. J Cell Biol 1988; 106: 2139-2151
8. Fujita T, Azuma Y, Fukuyama R et al. Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol 2004; 166: 85-95
9. Baron R. General principles of bone biology. In: Favus M (ed). Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th edn. ASBMR, 2003; 1-8
10. Nakashima K, Zhou X, Kunkel G et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002; 108: 17-29
11. Razzaque MS. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 2009; 5: 611-619
12. Razzaque MS. FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player? Am J Physiol Renal Physiol 2009; 296: F470-F476
13. Schaefer B, Schlosser K, Wuhl E et al. Long-term control of parathyroid hormone and calcium-phosphate metabolism after parathyroi-dectomy in children with chronic kidney disease. Nephrol Dial Transplant 2010; 25: 2590-2595
14. Carter JL, O'Riordan SE, Eaglestone GL et al. Bone mineral metabolism and its relationship to kidney disease in a residential care home population: a cross-sectional study. Nephrol Dial Transplant 2008; 23: 3554-3565
15. Fukagawa M, Kazama JJ, Kurokawa K. Renal osteodystrophy and secondary hyperparathyroidism. Nephrol Dial Transplant 2002; 17: 2-5
16. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2009; 5: 667-676
17. Yoneda T, Hiraga T. Crosstalk between cancer cells and bone micro-environment in bone metastasis. Biochem Biophys Res Commun 2005; 328: 679-687
18. Cirmanova V, Bayer M, Starka L et al. The effect of leptin on bone: an evolving concept of action. Physiol Res 2008; 57: S143-S151
19. Martin A, David V, Malaval L et al. Opposite effects of leptin on bone metabolism: a dose-dependent balance related to energy intake and insulin-like growth factor-I pathway. Endocrinology 2007; 148: 3419-3425
20. Price PA, Parthemore JG, Deftos LJ. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease. J Clin Invest 1980; 66: 878-883
21. Akesson K, Vergnaud P, Delmas PD et al. Serum osteocalcin increases during fracture healing in elderly women with hip fracture. Bone 1995; 16: 427-430
22. BoiskinI, EpsteinS,Ismail Fetal. Serum osteocalcin and bone mineral metabolism following successful renal transplantation. Clin Nephrol 1989; 31: 316-322
23. Lee NK, Sowa H, Hinoi E et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130: 456-469
24. Ferron M, Hinoi E, Karsenty G et al. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 2008; 105: 5266-5270
25. Rosen CJ, Motyl KJ. No bones about it: insulin modulates skeletal remodeling. Cell 2010; 142: 198-200
26. Ducy P, Desbois C, Boyce B et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996; 382: 448-452
27. Yoshida M, Booth SL, Meigs JB et al. Phylloquinone intake, insulin sensitivity, and glycemic status in adult men and women. Am J Clin Nutr 2008; 88: 210-215
28. Yoshida M, Jacques PF, Meigs JB et al. Effect of vitamin K supplementation on insulin resistance in older men and women. Diab Care 2008; 31: 2092-2096
29. Delmas PD, Wilson DM, Mann KG et al. Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab 1983; 57: 1028-1030
30. Coen G, Mazzaferro S, Bonucci E et al. Bone GLA protein in pre-dialysis chronic renal failure. Effects of 1, 25(OH)2D3 administration in a long-term follow-up. Kidney Int 1985; 28: 783-790
31. Bonnin MR, Gonzalez MT, Grino JM et al. Changes in serum os-teocalcin levels in the follow-up of kidney transplantation. Ann Clin Biochem 1997; 34: 651-655
32. Ferron M, Wei J, Yoshizawa T et al. An ELISA-based method to quantify osteocalcin carboxylation in mice. Biochem Biophys Res Commun 2010; 397: 691-696
33. Okura T, Kurata M, Enomoto D et al. Undercarboxylated osteocalcin is a biomarker of carotid calcification in patients with essential hypertension. Kidney Blood Press Res 2010; 33: 66-71
34. Razzaque MS. Phosphate toxicity: new insights into an old problem. Clin Sci (Lond) 2011; 120: 91-97
35. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 2009; 20: 1453-1464
36. Razzaque MS. The dualistic role of vitamin D in vascular calcifications. Kidney Int 2010; doi:10.1038/ki.2010.432
37. Wada T, McKee MD, Steitz S et al. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999; 84: 166-178
38. Gadeau AP, Chaulet H, Daret D et al. Time course of osteopontin, osteocalcin, and osteonectin accumulation and calcification after acute vessel wall injury. J Histochem Cytochem 2001; 49: 79-86
39. Bacchetta J, Boutroy S, Guebre-Egziabher F et al. The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease. Nephrol Dial Transplant 2009; 24: 3120-3125
40. Kanazawa I, Yamaguchi T, Yamauchi M et al. Serum undercar-boxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int 2010; doi:10.1007/s00198-010-1184-7
41. Foresta C, Strapazzon G, De Toni L et al. Evidence for osteocalcin production by adipose tissue and its role in human metabolism. J Clin Endocrinol Metab 2010; 95: 3502-3506
42. Holden RM, Sanfilippo AS, Hopman WM et al. Warfarin and aortic valve calcification in hemodialysis patients. J Nephrol 2007; 20: 417-422